The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: An overall survival update and long-term safety from the randomised, double-blind, placebo-controlled, phase 3 trial.
 
Jiani Wang
No Relationships to Disclose
 
Qingyuan Zhang
No Relationships to Disclose
 
Xichun Hu
No Relationships to Disclose
 
Qing Li
No Relationships to Disclose
 
Tao Sun
No Relationships to Disclose
 
Wei Li
No Relationships to Disclose
 
Quchang Ouyang
No Relationships to Disclose
 
Jingfen Wang
No Relationships to Disclose
 
Zhongsheng Tong
No Relationships to Disclose
 
Min Yan
No Relationships to Disclose
 
Huiping Li
No Relationships to Disclose
 
Xiaohua Zeng
No Relationships to Disclose
 
Changping Shan
No Relationships to Disclose
 
Xian Wang
No Relationships to Disclose
 
Jian Zhang
No Relationships to Disclose
 
Yue Zhang
No Relationships to Disclose
 
Liang Zhang
No Relationships to Disclose
 
Ying Tian
No Relationships to Disclose
 
Hongyan Shang
No Relationships to Disclose
 
Binghe Xu
Consulting or Advisory Role - AstraZeneca; Novartis
Speakers' Bureau - AstraZeneca